Price
Financials
Standalone, Rs crore| Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 30.34 | 28.74 | 29.46 | 30.62 | 31.15 | 28.40 | 28.24 | 33.20 |
| Expenses | 21.96 | 20.25 | 21.83 | 22.11 | 21.01 | 21.84 | 23.41 | 24.58 |
| Operating Profit | 8.38 | 8.49 | 7.63 | 8.51 | 10.14 | 6.56 | 4.83 | 8.62 |
| OPM % | 27.62% | 29.54% | 25.90% | 27.79% | 32.55% | 23.10% | 17.10% | 25.96% |
| Other Income | 0.01 | 0.19 | 0.09 | -0.02 | 0.03 | 0.08 | 0.23 | 0.26 |
| Interest | 0.65 | 0.51 | 0.50 | 0.38 | 0.19 | 0.05 | 0.11 | 0.07 |
| Depreciation | 0.91 | 0.87 | 0.85 | 0.87 | 0.85 | 1.09 | 1.09 | 1.08 |
| Profit before tax | 6.83 | 7.30 | 6.37 | 7.24 | 9.13 | 5.50 | 3.86 | 7.73 |
| Tax % | 33.67% | 31.23% | 41.13% | 35.22% | 33.95% | 29.27% | 26.94% | 15.27% |
| Net Profit | 4.53 | 5.02 | 3.75 | 4.69 | 6.03 | 3.89 | 2.82 | 6.55 |
| EPS in Rs | 6.29 | 6.97 | 5.21 | 6.51 | 8.37 | 5.40 | 3.92 | 9.10 |
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 46 | 38 | 50 | 62 | 79 | 108 | 120 | 116 | 118 | 135 | 150 | 156 |
| Expenses | 33 | 31 | 36 | 51 | 66 | 83 | 85 | 90 | 110 | 116 | 131 | 144 |
| Operating Profit | 13 | 7 | 15 | 11 | 13 | 25 | 35 | 26 | 9 | 19 | 19 | 12 |
| OPM % | 29% | 17% | 29% | 18% | 17% | 23% | 29% | 22% | 7% | 14% | 13% | 8% |
| Other Income | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 4 | 2 |
| Interest | 2 | 2 | 2 | 2 | 4 | 3 | 2 | 1 | 17 | 17 | 27 | 28 |
| Depreciation | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 5 | 16 | 16 | 39 | 33 |
| Profit before tax | 10 | 3 | 11 | 6 | 7 | 19 | 30 | 21 | -24 | -14 | -43 | -48 |
| Tax % | 38% | 34% | 35% | 34% | 31% | 31% | 35% | 19% | -22% | 0% | 0% | 0% |
| Net Profit | 6 | 2 | 7 | 4 | 5 | 13 | 20 | 17 | -19 | -14 | -43 | -48 |
| EPS in Rs | 8.51 | 3.14 | 9.94 | 5.96 | 6.94 | 17.87 | 27.08 | 23.64 | -25.74 | -19.19 | -60.30 | -66.07 |
| Dividend Payout % | 18% | 48% | 15% | 25% | 14% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 15% | 5% | 10% | 4% | ||
| Compounded Profit Growth | % | % | % | -9% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | % | % | % |
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Reserves | 20 | 21 | 27 | 30 | 34 | 47 | 66 | 83 | 64 | 50 | 7 | -41 |
| Borrowings | 19 | 14 | 11 | 26 | 24 | 18 | 43 | 206 | 251 | 274 | 289 | 296 |
| Other Liabilities | 13 | 10 | 14 | 18 | 18 | 23 | 26 | 43 | 37 | 33 | 23 | 53 |
| Total Liabilities | 60 | 53 | 59 | 81 | 83 | 96 | 143 | 339 | 359 | 364 | 326 | 315 |
| Fixed Assets | 37 | 35 | 35 | 50 | 50 | 46 | 50 | 278 | 289 | 275 | 268 | 246 |
| CWIP | 2 | 2 | 3 | 2 | 3 | 8 | 26 | 3 | 11 | 27 | 4 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 20 | 15 | 21 | 28 | 30 | 41 | 67 | 58 | 59 | 61 | 54 | 67 |
| Total Assets | 60 | 53 | 59 | 81 | 83 | 96 | 143 | 339 | 359 | 364 | 326 | 315 |
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 7 | 6 | 9 | |||||||||
| Cash from Investing Activity | -12 | -0 | -2 | |||||||||
| Cash from Financing Activity | 5 | -6 | -4 | |||||||||
| Net Cash Flow | 0 | -1 | 2 | |||||||||
| Free Cash Flow | -5 | 6 | 7 | |||||||||
| CFO/OP | 74% | 110% | 85% |
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 73 | 79 | 85 | 60 | 87 | 102 | 99 | 81 | 90 | 62 | 67 |
| Inventory Days | 186 | 118 | 112 | 120 | 124 | 96 | 73 | 125 | 197 | 140 | 127 | 181 |
| Days Payable | 131 | 49 | 96 | 88 | 83 | 76 | 74 | 67 | 57 | 33 | 102 | 94 |
| Cash Conversion Cycle | 114 | 142 | 95 | 117 | 101 | 107 | 100 | 156 | 221 | 198 | 86 | 153 |
| Working Capital Days | 79 | 84 | 68 | 78 | 65 | 76 | 78 | 54 | 53 | 68 | 65 | 52 |
| ROCE % | 28% | 12% | 29% | 17% | 17% | 32% | 34% | 10% | -2% | 1% | -5% | -7% |
Fundamentals
Market Cap₹ Cr.
Current Price₹ 515
Book Value₹ -46.6
ROCE-6.75 %
ROE%
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)4%
Compounded Profit Growth (TTM)-9%
Standalone figures.
Valuation
P/B, 3-year average7.26x
P/E, 5-year average21.79x
P/B, 5-year average6.22x
Profitability
Operating margin (excl. other income)7.57%
Operating margin (incl. other income)8.63%
EBITDA margin27.60%
Pre-tax margin23.61%
Net profit margin15.35%
Net margin, latest quarter13.70%
ROE488.40%
ROCE-6.81%
ROA-14.83%
ROE, 3-year average115.16%
ROCE, 3-year average-3.60%
ROA, 3-year average-10.41%
ROE, 5-year average68.67%
ROCE, 5-year average-0.54%
ROA, 5-year average-5.90%
ROIC (approx.)11.22%
Other income / net worth-4.95%
Growth
Sales growth (latest year)4.00%
Sales CAGR, 3 years9.62%
Sales CAGR, 5 years5.35%
Sales growth QoQ-8.83%
Profit growth QoQ-35.49%
Sales growth YoY (latest quarter)-1.18%
Profit growth YoY (latest quarter)-22.51%
Per share
EPS (TTM)Rs 25.50
EPS (latest year)Rs -66.07
EPS (latest quarter)Rs 5.40
EPS, 3-year averageRs -48.52
EPS, 5-year averageRs -29.53
Book value per shareRs -46.57
Sales per shareRs 166.15
Free cash flow per shareRs 9.72
Efficiency
Asset turnover0.49x
Fixed asset turnover0.63x
Inventory turnover3.25x
Inventory days112 days
Debtor days67 days
Debtors turnover5.48x
Creditor days94 days
Cash conversion cycle153 days
Working capital days52 days
Leverage
Total debtRs 296 Cr
Cash and bankRs 1 Cr
Net debtRs 295 Cr
Debt to equity-8.82x
Net debt / EBITDA8.94x
Interest coverage26.21x
Owners' fund to total sources-10.63%
Debt to assets93.81%
Cash flow
Free cash flow (latest year)Rs 7 Cr
FCFE (approx.: FCF + change in debt)Rs 14 Cr
Statement figures
Net sales (TTM)Rs 120 Cr
Net sales (latest year)Rs 156 Cr
Sales (latest quarter)Rs 28 Cr
Operating profit excl. other income (latest year)Rs 12 Cr
Operating profit (latest quarter)Rs 7 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 33 Cr
PBDT (TTM)Rs 32 Cr
Profit before tax (TTM)Rs 28 Cr
Net profit (TTM)Rs 18 Cr
Net profit (latest year)Rs -48 Cr
Net profit (latest quarter)Rs 4 Cr
Depreciation (TTM)Rs 4 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 87 Cr
Total expenditure (latest year)Rs 144 Cr
Total income (latest year)Rs 157 Cr
Share capitalRs 7 Cr
ReservesRs -41 Cr
Shareholders' fundsRs -34 Cr
Total assetsRs 315 Cr
Net blockRs 246 Cr
Capital work in progressRs 3 Cr
ReceivablesRs 28 Cr
InventoryRs 27 Cr
Other liabilitiesRs 53 Cr
Shares outstanding (crore)0.72
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 2 of 6| serious | Negative equity Shareholders' equity is negative |
| look | Inventory outrunning sales Inventory grew 54% vs sales +4% in 2019 |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Dec 2014Sales ₹33 Cr +8.4% vs Dec 2013.
Net profit ₹7 Cr +39.7%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Ahlcon Parenterals (India) Ltd?
Ahlcon Parenterals (India) Ltd (524448) has a market capitalisation of Rs Cr. at the close.
What were Ahlcon Parenterals (India) Ltd's latest quarterly results?
In the Dec 2014 quarter, Ahlcon Parenterals (India) Ltd sales was Rs 33 Cr (+8.4% vs Dec 2013) and net profit was Rs 7 Cr.